A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial

BackgroundAsthma prevalence, morbidity, and mortality disproportionately impact African American/Black (AA/B) and Hispanic/Latinx (H/L) communities. Adherence to daily inhaled corticosteroid (ICS), recommended by asthma guidelines in all but the mildest cases of asthma, is generally poor. As-needed ICS has shown promise as a patient-empowering asthma management strategy, but it has not been rigorously studied in AA/B or H/L patients or in a real-world setting.Design and AimThe PeRson EmPowered Asthma RElief (PREPARE) Study is a randomized, open-label, pragmatic study which aims to assess whether a patient-guided, reliever-triggered ICS strategy called PARTICS (Patient-Activated Reliever-Triggered Inhaled CorticoSteroid) can improve asthma outcomes in AA/B and H/L adult patient populations.

Source: Contemporary Clinical Trials - December 11, 2020 Category: Radiology Authors: Elliot Israel, Juan Carlos Cardet, Jennifer K. Carroll, Anne L. Fuhlbrigge, Wilson D. Pace, Nancy E. Maher, Lilin She, Frank W. Rockhold, Maureen Fagan, Victoria E. Forth, Paulina Arias Hernandez, Brian K. Manning, Jacqueline Rodriguez-Louis, Joel B. Shie Source Type: research